These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 11498700)

  • 1. [Novel antibiotics active against Gram-positive bacteria].
    Garcia Sánchez JE; Fresnadillo Martínez MJ
    Rev Esp Quimioter; 2000 Dec; 13(4):344-51. PubMed ID: 11498700
    [No Abstract]   [Full Text] [Related]  

  • 2. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 3. Vancomycin-resistant enterococcal infections.
    Murray BE
    N Engl J Med; 2000 Mar; 342(10):710-21. PubMed ID: 10706902
    [No Abstract]   [Full Text] [Related]  

  • 4. Effectiveness of fluoroquinolones against gram-positive bacteria.
    Bush K; Goldschmidt R
    Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
    Frippiat F; Meunier F; Derue G
    J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
    [No Abstract]   [Full Text] [Related]  

  • 6. What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.
    Gleckman R
    Postgrad Med; 2001 Mar; 109(3):87-91; quiz 28. PubMed ID: 11265366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteraemia successfully treated with moxifloxacin.
    van Nieuwkoop C; Visser LG; Groeneveld JH; Kuijper EJ
    J Infect; 2008 Feb; 56(2):155-6. PubMed ID: 18083235
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH; Wang JT; Chen YC; Chang SC; Luh KT
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
    Talan DA
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin (Avelox) for the treatment of bacterial skin infections.
    Parish LC; Witkowski JA; Routh HB
    Skin Therapy Lett; 2001 Oct; 6(11):1-2. PubMed ID: 11719825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Respiratory tract infections. Increasingly more established antibiotics fail].
    MMW Fortschr Med; 2002 Oct; 144(42):65. PubMed ID: 12534005
    [No Abstract]   [Full Text] [Related]  

  • 12. Aminoglycoside resistant enterococcal endocarditis.
    Eliopoulos GM
    Infect Dis Clin North Am; 1993 Mar; 7(1):117-33. PubMed ID: 8463648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.
    Scoper SV
    Adv Ther; 2008 Oct; 25(10):979-94. PubMed ID: 18836691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
    Oliveira AD; D'Azevedo PA; Francisco W
    Cornea; 2007 Feb; 26(2):194-8. PubMed ID: 17251812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
    Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
    Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New antibiotics in primary care].
    Horcajada JP; Martínez JA
    Rev Esp Quimioter; 2003 Mar; 16(1):118-22. PubMed ID: 12760359
    [No Abstract]   [Full Text] [Related]  

  • 17. In vitro activity of moxifloxacin against Stenotrophomonas maltophilia blood isolates from patients with hematologic malignancies.
    Venditti M; Monaco M; Micozzi A; Tarasi A; Friedrich A; Martino P
    Clin Microbiol Infect; 2001 Jan; 7(1):37-9. PubMed ID: 11284945
    [No Abstract]   [Full Text] [Related]  

  • 18. Gram-positive bacterial resistance: future treatment options.
    Bassetti M; Melica G; Di Biagio A; Rosso R; Gatti G; Bassetti D
    Curr Opin Investig Drugs; 2003 Aug; 4(8):944-52. PubMed ID: 14508878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with quinupristin/dalfopristin after bacteremia persisted with alatrofloxacin therapy.
    Zaman MM; Recco R; Tejwani U; Scuto TJ; Ahmed S; Hypolite A; Jayaraman G
    Clin Infect Dis; 1999 Oct; 29(4):954-5. PubMed ID: 10589932
    [No Abstract]   [Full Text] [Related]  

  • 20. [Playing it safe in bronchopulmonary infections].
    MMW Fortschr Med; 2003 May; 145(18):57. PubMed ID: 12838909
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.